LIVE TV
ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Jobs
  • Indian Railways
  • World
    • Economy
    • Politics
    • Markets
  • videos
  • photos
  • Authors
  • More ...
    • VIDEOS
    • PHOTOS
Read in App
Business News » Markets News

Aurobindo Pharma share price: Sharekhan retains Buy recommendation with price target of Rs 1100

Aurobindo Pharma’s US business is expected to stage a marked improvement. A mix of factors, which includes a sturdy pipeline of new products, expected traction in the lucrative injectables space driven by strong new product pipeline and commissioning of a new facility coupled with growth in the recently launched products would boost US business’ sales

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
Aurobindo Pharma share price: Sharekhan retains Buy recommendation with price target of Rs 1100
Aurobindo Pharma plans to launch around 50 products in the US in FY2021 and expects to sustain the launch momentum into FY2022E as well: Reuters
Reported By: ZeeBiz WebTeam
Written By: Rahul Kamdar
Edited By: Harish Dugh
Updated: Wed, Mar 31, 2021
03:34 pm
Mumbai, ZeeBiz WebDesk
RELATED NEWS
JPMorgan on Aurobindo Pharma stock re-rating trigger and target price JPMorgan on Aurobindo Pharma stock re-rating trigger and target price
Stock Of The Day: Anil Singhvi reveals his top recommendation for investors today - Aurobindo Pharma Stock Of The Day: Anil Singhvi reveals his top recommendation for investors today - Aurobindo Pharma
Aurobindo Pharma Share price: Sharekhan retains their Buy recommendation with a revised Price target of Rs 1100 Aurobindo Pharma Share price: Sharekhan retains their Buy recommendation with a revised Price target of Rs 1100
Aurobindo Pharma, Biocon, Dr Reddy’s Lab and Divi’s Laboratories: Resilient demand points to another good year for Pharma Sector says HSBC Aurobindo Pharma, Biocon, Dr Reddy’s Lab and Divi’s Laboratories: Resilient demand points to another good year for Pharma Sector says HSBC
Nifty to Sensex - All you need to know about markets today Nifty to Sensex - All you need to know about markets today

Aurobindo Pharma’s US business is expected to stage a marked improvement. A mix of factors, which includes a sturdy pipeline of new products, expected traction in the lucrative injectables space driven by strong new product pipeline and commissioning of a new facility coupled with growth in the recently launched products would boost US business’ sales. Aurobindo Share price today is Rs 877, up Rs 7 or 0.8%.

Aurobindo Pharma plans to launch around 50 products in the US in FY2021 and expects to sustain the launch momentum into FY2022E as well. The new launches would include the injectables as well, which are a key growth driver. In the injectables space the company has 70 assets under development, 50 assets under review and 80 approved products, thus pointing towards a sturdy product pipeline which would unfold going ahead.

See Zee Business Live TV Streaming Below:

With the demand from Europe and emerging markets also picking up, Aurobindo Pharma is setting up a green field plant at Vizag to capitalize on this opportunity and be able to cater to the incremental demand. The said plant is expected to be ready within the next 15 months.

Also, recent reports suggest a pick up in the complex generic space with the overall industry size likely to increase to around $20bn over the next 3 years from around $15-$16 bn now. Aurobindo Pharma currently has a small presence in the complex generics space, but is looking to enhance its presence gradually in the segment by focusing on areas of biosimilars, inhalers, transdermal patches and Injectables, which bodes well from a growth perspective.

The expected commissioning of a 450 mn dose vaccine capacity by end of June 2021 provides a new growth avenue for Aurobindo Pharma. Successful clearance from USFDA for its plants is awaited as the company has submitted its responses. Over the long term, a focus on building and developing a strong portfolio of specialty products (biosimilars, oncology, inhalers, transdermal patches, etc) would be key growth drivers.

Technically, Aurobindo Pharma is trading above 200EMA, indicating that the stock's positive long-term trend is likely to continue. Recently Aurobindo Pharma has bounced back from the short-term support of 50 DMA and is currently trading into a rising channel. Ashis recommends a buy above Rs 875. Ashis expects a Target of Rs 1020 from a medium-term perspective with a Stop Loss of Rs 790.

Aurobindo Pharma’s Key Risks:

Delay in resolution of USFDA issues and product approvals; change in regulatory landscape; and negative outcome of key facility inspection by USFDA can affect earnings prospects.

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Aurobindo Pharma
RELATED NEWS
JPMorgan on Aurobindo Pharma stock re-rating trigger and target price JPMorgan on Aurobindo Pharma stock re-rating trigger and target price
Stock Of The Day: Anil Singhvi reveals his top recommendation for investors today - Aurobindo Pharma Stock Of The Day: Anil Singhvi reveals his top recommendation for investors today - Aurobindo Pharma
Aurobindo Pharma Share price: Sharekhan retains their Buy recommendation with a revised Price target of Rs 1100 Aurobindo Pharma Share price: Sharekhan retains their Buy recommendation with a revised Price target of Rs 1100
Aurobindo Pharma, Biocon, Dr Reddy’s Lab and Divi’s Laboratories: Resilient demand points to another good year for Pharma Sector says HSBC Aurobindo Pharma, Biocon, Dr Reddy’s Lab and Divi’s Laboratories: Resilient demand points to another good year for Pharma Sector says HSBC
Nifty to Sensex - All you need to know about markets today Nifty to Sensex - All you need to know about markets today

LATEST NEWS

Covid-19 pandemic in NCR: 2 hospitals in Noida declare oxygen shortage

Chhattisgarh Class 10th Board Exam Cancelled 2021: CGBSE CANCELS class 10 board exam due to rise in COVID cases - see details here

Gold price today 23-04-2021: Expert suggests buying at around Rs 47650 for target of Rs 48200

CBSE Class 10 Board Exam 2021 Result: BIG NEWS! Students DON'T MISS this LATEST UPDATE - all details here

Gold Price Today, April 23: Check rates in Mumbai, Delhi, Chennai and Lucknow

CBSE Board Exams 2021: Students DON'T MISS this BIG UPDATE on objective criterion and the new assessment and evaluation practices

Anil Singhvi decodes fall in US markets on Thursday, reveals strategy for investors

Ola Electric to set up one lakh charging points in 400 cities

PUBG Mobile 1.4 update: Check global version beta update APK download link for worldwide users

Shravan Rathod of Nadeem-Shravan fame DIES due to Covid 19-related complications

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
Copyright © Zee Media Corporation Ltd. All rights reserved